Amgen is committed to unlocking the potential of biology for patients suffering from various serious illnesses including heart failure by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
The Cardiometabolic disorders department at Amgen is seeking an Sr. Associate Scientist skilled in vivo Cardiovascular Biology. The Sr. Associate Scientist will join a team of experienced scientists and be involved in the discovery of novel therapeutics agents for heart failure.
Utilize in-vivo models for cardiovascular disease (e.g. myocardial infarction models) in support of early and late stage preclinical drug discovery projects.
Plan, conduct experiments, analyze data, present data, maintain in vivo study records, protocols, and ensure that all of the studies are conducted in compliance with the respective protocol and applicable guidelines and regulations.
Master's degree and 3 years of scientific experience
Bachelor's degree and 5 years of scientific experience
Ph.D. or Master's in cardiovascular physiology, vascular biology, life sciences, or related field.
Strong record in utilizing in-vivo cardiovascular surgical models (e.g. myocardial infarction, hypertrophy, microsurgeries, etc) models to study cardiovascular disease.
Experience with pressure-volume loops, echocardiography, and microsurgical skills.
Proficiency in Graph Pad, Excel and PowerPoint, as well as, with basic tools for statistical data analysis.
Excellent communication skills, troubleshooting skills, pro-active attitude and ability to work productively as part of a high-performance teams.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.